*	
---	--

Abstract -

Full text links
Final Version
J Pharma Exp Ther

J Pharmacol Exp Ther. 2015 Mar;352(3):420-8. doi: 10.1124/jpet.114.219303. Epub 2014 Dec 16.

Curcumin attenuates opioid tolerance and dependence by inhibiting Ca2+/calmodulin-dependent protein kinase II α activity.

<u>Hu X¹, Huang F¹, Szymusiak M¹, Liu Y², Wang ZJ².</u>

Author information

¹Department of Biopharmaceutical Sciences (X.H., F.H., Y.L., Z.J.W.), Cancer Center (Z.J.W.), and Department of Chemical Engineering (M.S., Y.L.), University of Illinois, Chicago, Illinois.

²Department of Biopharmaceutical Sciences (X.H., F.H., Y.L., Z.J.W.), Cancer Center (Z.J.W.), and Department of Chemical Engineering (M.S., Y.L.), University of Illinois, Chicago, Illinois zjwang@uic.edu liuying@uic.edu.

Abstract

Chronic use of opioid analgesics has been hindered by the development of opioid addiction and tolerance. We have reported that curcumin, a natural flavonoid from the rhizome of Curcuma longa, attenuated opioid tolerance, although the underlying mechanism remains unclear. In this study, we tested the hypothesis that curcumin may inhibit Ca(2+)/calmodulin-dependent protein kinase II α (CaMKII α), a protein kinase that has been previously proposed to be critical for opioid tolerance and dependence. In this study, we used stateof-the-art polymeric formulation technology to produce poly(lactic-co-glycolic acid) (PLGA)-curcumin nanoparticles (nanocurcumin) to overcome the drug's poor solubility and bioavailability, which has made it extremely difficult for studying in vivo pharmacological actions of curcumin. We found that PLGA-curcumin nanoparticles reduced the dose requirement by 11- to 33-fold. Pretreatment with PLGA-curcumin (by mouth) prevented the development of opioid tolerance and dependence in a dose-dependent manner, with ED50 values of 3.9 and 3.2 mg/kg, respectively. PLGA-curcumin dose-dependently attenuated already-established opioid tolerance (ED50 = 12.6 mg/kg p.o.) and dependence (ED50 = 3.1 mg/kg p.o.). Curcumin or PLGA-curcumin did not produce antinociception by itself or affect morphine (1-10 mg/kg) antinociception. Moreover, we found that the behavioral effects of curcumin on opioid tolerance and dependence correlated with its inhibition of morphine-induced CaMKIIa activation in the brain. These results suggest that curcumin may attenuate opioid tolerance and dependence by suppressing CaMKIIa activity.

Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

PMID: 25515789 [PubMed - indexed for MEDLINE] PMCID: PMC4352596 [Available on 2016-03-01]



Publication Types, MeSH Terms, Substances, Grant Support

LinkOut - more resources

≤

PubMed Commons

Q 0 comments

PubMed Commons home

How to join PubMed Commons